Prevalence and clinical implications of abnormal body composition phenotypes in patients with COVID-19: a systematic review.
COVID-19
adipose tissue
bioelectrical impedance analysis
body composition
computed tomography
hospitalization
mortality
muscle
phase angle
ultrasound
Journal
The American journal of clinical nutrition
ISSN: 1938-3207
Titre abrégé: Am J Clin Nutr
Pays: United States
ID NLM: 0376027
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
15
07
2022
revised:
01
03
2023
accepted:
03
04
2023
medline:
5
6
2023
pubmed:
11
4
2023
entrez:
10
4
2023
Statut:
ppublish
Résumé
The impact of body composition (BC) abnormalities on COVID-19 outcomes remains to be determined. We summarized the evidence on BC abnormalities and their relationship with adverse clinical outcomes in patients with COVID-19. A systematic search was conducted up until 26 September, 2022 for observational studies using BC techniques to quantify skeletal muscle mass (or related compartments), muscle radiodensity or echo intensity, adipose tissue (AT; or related compartments), and phase angle (PhA) in adults with COVID-19. Methodological quality of studies was assessed using the Newcastle-Ottawa Scale. A synthesis without meta-analysis was conducted to summarize the prevalence of BC abnormalities and their significant associations with clinical outcomes. We included 62 studies (69.4% low risk of bias) with 12-1138 participants, except 3 studies with ≤490,301 participants. Using CT and different cutoff values, prevalence ranged approximately from 22% to 90% for low muscle mass, 12% to 85% for low muscle radiodensity, and 16% to 70% for high visceral AT. Using BIA, prevalence of high FM was 51%, and low PhA was 22% to 88%. Mortality was inversely related to PhA (3/4 studies) and positively related to intra- and intermuscular AT (4/5 studies), muscle echo intensity (2/2 studies), and BIA-estimated FM (2/2 studies). Intensive care unit (ICU) admission was positively related to visceral AT (6/7 studies) and total AT (2/3 studies). Disease severity and hospitalization outcomes were positively related to intra- and intermuscular AT (2/2 studies). Inconsistent associations were found for the rest of the BC measures and hospitalization outcomes. Abnormalities in BC were prevalent in patients with COVID-19. Although conflicting associations were observed among certain BC abnormalities and clinical outcomes, higher muscle echo intensity (reflective of myosteatosis) and lower PhA were more consistently associated with greater mortality risk. Likewise, high intra- and intermuscular AT and visceral AT were associated with mortality and ICU admission, respectively. This trial was registered at PROSPERO as CRD42021283031.
Sections du résumé
BACKGROUND
The impact of body composition (BC) abnormalities on COVID-19 outcomes remains to be determined.
OBJECTIVES
We summarized the evidence on BC abnormalities and their relationship with adverse clinical outcomes in patients with COVID-19.
METHODS
A systematic search was conducted up until 26 September, 2022 for observational studies using BC techniques to quantify skeletal muscle mass (or related compartments), muscle radiodensity or echo intensity, adipose tissue (AT; or related compartments), and phase angle (PhA) in adults with COVID-19. Methodological quality of studies was assessed using the Newcastle-Ottawa Scale. A synthesis without meta-analysis was conducted to summarize the prevalence of BC abnormalities and their significant associations with clinical outcomes.
RESULTS
We included 62 studies (69.4% low risk of bias) with 12-1138 participants, except 3 studies with ≤490,301 participants. Using CT and different cutoff values, prevalence ranged approximately from 22% to 90% for low muscle mass, 12% to 85% for low muscle radiodensity, and 16% to 70% for high visceral AT. Using BIA, prevalence of high FM was 51%, and low PhA was 22% to 88%. Mortality was inversely related to PhA (3/4 studies) and positively related to intra- and intermuscular AT (4/5 studies), muscle echo intensity (2/2 studies), and BIA-estimated FM (2/2 studies). Intensive care unit (ICU) admission was positively related to visceral AT (6/7 studies) and total AT (2/3 studies). Disease severity and hospitalization outcomes were positively related to intra- and intermuscular AT (2/2 studies). Inconsistent associations were found for the rest of the BC measures and hospitalization outcomes.
CONCLUSIONS
Abnormalities in BC were prevalent in patients with COVID-19. Although conflicting associations were observed among certain BC abnormalities and clinical outcomes, higher muscle echo intensity (reflective of myosteatosis) and lower PhA were more consistently associated with greater mortality risk. Likewise, high intra- and intermuscular AT and visceral AT were associated with mortality and ICU admission, respectively. This trial was registered at PROSPERO as CRD42021283031.
Identifiants
pubmed: 37037395
pii: S0002-9165(23)46332-0
doi: 10.1016/j.ajcnut.2023.04.003
pmc: PMC10082471
pii:
doi:
Types de publication
Systematic Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1288-1305Informations de copyright
Copyright © 2023 American Society for Nutrition. Published by Elsevier Inc. All rights reserved.
Références
Eur J Clin Nutr. 2018 Feb;72(2):288-296
pubmed: 29242526
J Gerontol A Biol Sci Med Sci. 2021 Jul 13;76(8):e110-e116
pubmed: 33780535
Clin Nutr. 2022 Dec;41(12):2965-2972
pubmed: 34465493
J Cachexia Sarcopenia Muscle. 2021 Aug;12(4):1056-1063
pubmed: 34102017
Bratisl Lek Listy. 2022;123(3):197-204
pubmed: 35343752
Nutr Clin Pract. 2019 Feb;34(1):48-58
pubmed: 30586471
Clin Nutr ESPEN. 2021 Jun;43:163-168
pubmed: 34024509
Eur J Radiol. 2020 Oct;131:109271
pubmed: 32942198
J Transl Med. 2020 Aug 3;18(1):299
pubmed: 32746930
Clin Nutr. 2021 Apr;40(4):2328-2336
pubmed: 33129597
JCSM Rapid Commun. 2022 Jan-Jun;5(1):3-9
pubmed: 34541518
Eur J Radiol. 2021 Dec;145:110031
pubmed: 34801878
Abdom Radiol (NY). 2021 Feb;46(2):818-825
pubmed: 32748252
Commun Biol. 2022 Jan 12;5(1):45
pubmed: 35022513
Obes Med. 2021 Aug;25:100358
pubmed: 34250312
J Clin Med. 2021 Nov 24;10(23):
pubmed: 34884199
J Cachexia Sarcopenia Muscle. 2017 Aug;8(4):527-528
pubmed: 28675689
Geroscience. 2020 Dec;42(6):1547-1578
pubmed: 33001410
Int J Obes (Lond). 2021 Oct;45(10):2238-2243
pubmed: 34244597
Open Forum Infect Dis. 2021 May 28;8(7):ofab275
pubmed: 34258315
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Radiology. 2021 Aug;300(2):E328-E336
pubmed: 33724065
Int J Obes (Lond). 2022 May;46(5):943-950
pubmed: 35031696
Nutr Clin Pract. 2022 Feb;37(1):110-116
pubmed: 34617311
BMJ Nutr Prev Health. 2022 Jan 19;5(1):10-18
pubmed: 35814718
Metabolism. 2021 Feb;115:154440
pubmed: 33246009
Ageing Res Rev. 2013 Sep;12(4):898-906
pubmed: 23948422
BMC Geriatr. 2017 Jun 5;17(1):118
pubmed: 28583070
Support Care Cancer. 2022 Apr;30(4):3119-3129
pubmed: 34862578
Clin Nutr. 2022 Jun;41(6):1425-1433
pubmed: 35450768
Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1008-1015
pubmed: 28506965
J Clin Epidemiol. 2020 Apr;120:94-103
pubmed: 31866469
Surg Obes Relat Dis. 2018 Nov;14(11):1755-1763
pubmed: 30193906
J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):159-168
pubmed: 35018725
Clin Nutr ESPEN. 2021 Dec;46:185-192
pubmed: 34857194
J Gerontol A Biol Sci Med Sci. 2014 May;69(5):547-58
pubmed: 24737557
Clin Geriatr Med. 2022 Aug;38(3):545-557
pubmed: 35868672
Mol Cell Biochem. 2022 Apr;477(4):1155-1193
pubmed: 35084674
BMC Med Imaging. 2022 Aug 12;22(1):144
pubmed: 35962312
J Gerontol A Biol Sci Med Sci. 2021 Feb 25;76(3):e78-e84
pubmed: 33355656
Int J Obes (Lond). 2008 Aug;32 Suppl 3:S56-9
pubmed: 18695655
PLoS One. 2021 May 14;16(5):e0251768
pubmed: 33989341
Biochemistry (Mosc). 2020 Dec;85(12):1543-1553
pubmed: 33705292
Clin Nutr ESPEN. 2021 Oct;45:499-502
pubmed: 34620361
J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):187-189
pubmed: 28145079
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Metabolism. 2020 Sep;110:154317
pubmed: 32673651
Int J Chron Obstruct Pulmon Dis. 2019 Apr 03;14:781-789
pubmed: 31040657
JAMA Neurol. 2021 Aug 1;78(8):948-960
pubmed: 34115106
BMJ Open. 2021 Oct 11;11(10):e048221
pubmed: 34635516
Front Cell Infect Microbiol. 2022 Feb 25;11:777070
pubmed: 35282595
Einstein (Sao Paulo). 2022 May 30;20:eAO6953
pubmed: 35649055
Diagnostics (Basel). 2022 Sep 18;12(9):
pubmed: 36140656
J Cachexia Sarcopenia Muscle. 2022 Aug;13(4):1974-1982
pubmed: 35698920
Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2513-2524
pubmed: 30964178
Eur Respir Rev. 2014 Dec;23(134):519-30
pubmed: 25445951
Front Endocrinol (Lausanne). 2020 May 21;11:332
pubmed: 32508753
Diabetes Care. 2020 Oct;43(10):e129-e130
pubmed: 32753457
Metabolism. 2020 Oct;111:154319
pubmed: 32712222
Clin Nutr. 2022 Dec;41(12):3106-3114
pubmed: 33642143
Clin Interv Aging. 2018 Oct 02;13:1871-1878
pubmed: 30323573
Clin Nutr. 2021 Jul;40(7):4799-4806
pubmed: 34271241
Dig Dis Sci. 2022 Sep;67(9):4484-4491
pubmed: 34820728
Turk Thorac J. 2022 Mar;23(2):123-129
pubmed: 35404244
Comput Med Imaging Graph. 2019 Jul;75:47-55
pubmed: 31132616
Front Endocrinol (Lausanne). 2022 Aug 03;13:899625
pubmed: 35992131
Clin Infect Dis. 2020 Jul 28;71(15):740-747
pubmed: 32211844
Int J Gen Med. 2020 Dec 23;13:1643-1651
pubmed: 33380822
Int Immunopharmacol. 2021 Dec;101(Pt A):108172
pubmed: 34601331
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
Acad Radiol. 2023 Jan;30(1):77-82
pubmed: 35667979
Extrem Physiol Med. 2015 Oct 09;4:16
pubmed: 26457181
J Appl Physiol (1985). 2004 Dec;97(6):2333-8
pubmed: 15310748
J Rehabil Med. 2020 Apr 15;52(4):jrm00046
pubmed: 32286674
Metabolism. 2016 Jul;65(7):968-86
pubmed: 27282868
Eur J Radiol. 2020 Nov;132:109274
pubmed: 32961451
Acta Physiol (Oxf). 2014 Mar;210(3):489-97
pubmed: 24393306
Nutrients. 2021 Nov 15;13(11):
pubmed: 34836338
Front Physiol. 2021 Mar 11;12:640973
pubmed: 33776796
J Nutr Health Aging. 2021;25(4):507-515
pubmed: 33786569
Curr Opin Clin Nutr Metab Care. 2021 May 1;24(3):229-235
pubmed: 33587365
PLoS One. 2019 Jun 13;14(6):e0216991
pubmed: 31194755
Front Physiol. 2021 May 06;12:651167
pubmed: 34025446
Endocr Connect. 2022 Sep 26;11(10):
pubmed: 36040475
Front Physiol. 2022 May 02;13:829534
pubmed: 35586712
Sci Rep. 2017 Aug 22;7(1):9102
pubmed: 28831095
Nutrition. 2021 Nov-Dec;91-92:111449
pubmed: 34583135
J Crit Care. 2022 Feb;67:14-20
pubmed: 34600218
Sci Rep. 2022 Apr 19;12(1):6443
pubmed: 35440794
J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):169-179
pubmed: 34881516
Front Nutr. 2022 Jul 11;9:906659
pubmed: 35898710
J Clin Epidemiol. 2016 Jun;74:119-23
pubmed: 26780258
Obesity (Silver Spring). 2020 Nov;28(11):2040-2048
pubmed: 32677752
BMC Infect Dis. 2021 Dec 10;21(1):1240
pubmed: 34893021
Front Cardiovasc Med. 2020 Feb 25;7:22
pubmed: 32158768
Sci Rep. 2018 Jul 27;8(1):11369
pubmed: 30054580
Metabolism. 2020 Dec;113:154378
pubmed: 33002478
Am J Phys Med Rehabil. 2021 May 1;100(5):413-418
pubmed: 33587451
JPEN J Parenter Enteral Nutr. 2022 Aug;46(6):1232-1242
pubmed: 35437785
PLoS One. 2021 Jun 17;16(6):e0253433
pubmed: 34138945
J Nutr. 2021 Aug 7;151(8):2236-2244
pubmed: 34159388
Nutrition. 2022 Jan;93:111493
pubmed: 34655952
Tomography. 2022 Feb 08;8(1):414-422
pubmed: 35202199
Clin Nutr. 2022 Dec;41(12):2918-2923
pubmed: 35140034
Clin Nutr. 2022 Dec;41(12):2910-2917
pubmed: 35282986
Acad Radiol. 2021 Feb;28(2):166-172
pubmed: 33281041
Aging Clin Exp Res. 2021 Oct;33(10):2887-2898
pubmed: 34328636
JPEN J Parenter Enteral Nutr. 2022 May;46(4):828-835
pubmed: 34291834
Clin Nutr ESPEN. 2021 Jun;43:174-183
pubmed: 34024511
Clin Nutr ESPEN. 2022 Feb;47:252-259
pubmed: 35063210
ISRN Inflamm. 2013 Dec 22;2013:139239
pubmed: 24455420
Nutr Clin Pract. 2015 Apr;30(2):180-93
pubmed: 25613832
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
Res Synth Methods. 2021 Jan;12(1):29-33
pubmed: 32979023
PLoS One. 2021 Dec 2;16(12):e0260537
pubmed: 34855832
Obes Res Clin Pract. 2021 Jan-Feb;15(1):89-92
pubmed: 33358147
J Cachexia Sarcopenia Muscle. 2022 Oct;13(5):2436-2446
pubmed: 35851995
Turk Kardiyol Dern Ars. 2022 Apr;50(2):103-111
pubmed: 35400631
Front Nutr. 2019 May 24;6:75
pubmed: 31179284
Clin Nutr. 2022 Dec;41(12):3007-3015
pubmed: 34147286
Sci Rep. 2022 Sep 20;12(1):15718
pubmed: 36127500
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1871-1878
pubmed: 34523262
BMJ. 2020 Jan 16;368:l6890
pubmed: 31948937
J Clin Med. 2018 Oct 10;7(10):
pubmed: 30308959
In Vivo. 2022 Jan-Feb;36(1):375-380
pubmed: 34972737
Transpl Int. 2020 Dec;33(12):1610-1625
pubmed: 32970877